Matches in SemOpenAlex for { <https://semopenalex.org/work/W44762421> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W44762421 endingPage "5" @default.
- W44762421 startingPage "1062" @default.
- W44762421 abstract "LEVOFLOXACIN: A new anti-pneumococcal fluoroquinolone, levofloxacin, has received approval in France for the treatment of community-acquired pneumonia at the dose of 500 mg once or twice a day, depending on the severity of the disease, the germ susceptibility and the patient's weight. Levofloxacin has a powerful and rapid bactericidal activity, particularly against pneumococci, whatever the level of penicillin resistance. The pharmacokinetic properties of the compound allow once daily dosage. Pharmacodynamically, it has been clinically demonstrated that the most predictive parameter of efficacy is the Cmax/MIC ratio. PNEUMOCOCCAL PNEUMONIA: Because of the potential gravity of pneumococcal pneumonia, it might be preferrable to use levofloxacin at the dose of 500 mg twice daily. The efficacy of the two levofloxacin doses for the treatment of pneumococcal pneumonia was thus analyzed. Five clinical studies including 4 comparative trials, enrolling nearly 2,000 patients with community-acquired pneumonia were reported in the international approval document. Among these patients, 310 had documented pneumococcal pneumonia including 31% with bacteriemia. TASK FORCE REPORT: On the basis of available data, the level of proof is sufficient to prescribe levofloxacin at the dose of 500 mg once daily for the treatment of mild to moderately severe community-acquired pneumonia in ambulatory patients, including those with suspected pneumococcal pneumonia, with or without bacteriemia. It would be reasonable to propose the 500 mg twice daily dosage for severe community-acquired pneumonia warranting intensive care hospitalization in accordance with the criteria of the ERS Task Force Report. The well-founded rationale of this therapeutic strategy should be validated by the results of ongoing studies and by following the evolution of germ susceptibility to these new compounds." @default.
- W44762421 created "2016-06-24" @default.
- W44762421 creator A5062693172 @default.
- W44762421 creator A5066304155 @default.
- W44762421 date "2000-06-30" @default.
- W44762421 modified "2023-09-26" @default.
- W44762421 title "[Treatment of community-acquired pneumonia with levofloxacin: 500 mg once a day or 500 mg twice a day?]." @default.
- W44762421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10874918" @default.
- W44762421 hasPublicationYear "2000" @default.
- W44762421 type Work @default.
- W44762421 sameAs 44762421 @default.
- W44762421 citedByCount "3" @default.
- W44762421 crossrefType "journal-article" @default.
- W44762421 hasAuthorship W44762421A5062693172 @default.
- W44762421 hasAuthorship W44762421A5066304155 @default.
- W44762421 hasConcept C126322002 @default.
- W44762421 hasConcept C177713679 @default.
- W44762421 hasConcept C2776102371 @default.
- W44762421 hasConcept C2776520383 @default.
- W44762421 hasConcept C2777914695 @default.
- W44762421 hasConcept C2778314733 @default.
- W44762421 hasConcept C2779892413 @default.
- W44762421 hasConcept C2781253189 @default.
- W44762421 hasConcept C2781276175 @default.
- W44762421 hasConcept C501593827 @default.
- W44762421 hasConcept C71924100 @default.
- W44762421 hasConcept C86803240 @default.
- W44762421 hasConcept C89423630 @default.
- W44762421 hasConceptScore W44762421C126322002 @default.
- W44762421 hasConceptScore W44762421C177713679 @default.
- W44762421 hasConceptScore W44762421C2776102371 @default.
- W44762421 hasConceptScore W44762421C2776520383 @default.
- W44762421 hasConceptScore W44762421C2777914695 @default.
- W44762421 hasConceptScore W44762421C2778314733 @default.
- W44762421 hasConceptScore W44762421C2779892413 @default.
- W44762421 hasConceptScore W44762421C2781253189 @default.
- W44762421 hasConceptScore W44762421C2781276175 @default.
- W44762421 hasConceptScore W44762421C501593827 @default.
- W44762421 hasConceptScore W44762421C71924100 @default.
- W44762421 hasConceptScore W44762421C86803240 @default.
- W44762421 hasConceptScore W44762421C89423630 @default.
- W44762421 hasIssue "19" @default.
- W44762421 hasLocation W447624211 @default.
- W44762421 hasOpenAccess W44762421 @default.
- W44762421 hasPrimaryLocation W447624211 @default.
- W44762421 hasRelatedWork W2003639415 @default.
- W44762421 hasRelatedWork W2007551692 @default.
- W44762421 hasRelatedWork W2049829563 @default.
- W44762421 hasRelatedWork W2056331911 @default.
- W44762421 hasRelatedWork W2125209012 @default.
- W44762421 hasRelatedWork W2138573008 @default.
- W44762421 hasRelatedWork W2145851941 @default.
- W44762421 hasRelatedWork W2332266338 @default.
- W44762421 hasRelatedWork W2336143177 @default.
- W44762421 hasRelatedWork W44762421 @default.
- W44762421 hasVolume "29" @default.
- W44762421 isParatext "false" @default.
- W44762421 isRetracted "false" @default.
- W44762421 magId "44762421" @default.
- W44762421 workType "article" @default.